When to discontinue renal replacement therapy. what do we know?
Journal
Current opinion in critical care
ISSN: 1531-7072
Titre abrégé: Curr Opin Crit Care
Pays: United States
ID NLM: 9504454
Informations de publication
Date de publication:
01 12 2023
01 12 2023
Historique:
medline:
2
11
2023
pubmed:
1
11
2023
entrez:
1
11
2023
Statut:
ppublish
Résumé
Acute kidney injury is common in intensive care patients. Supportive care involves the use of renal replacement therapies as organ support. Initiation of renal replacement therapy has been the subject of much interest over the last few years with several randomised controlled studies examining the optimal time to commence treatment. In contrast to this, little evidence has been generated regarding cessation of therapy. Given that this treatment is complex, not without risk and expensive it seems timely that efforts should be expended at examining this vexing issue. Although several studies have been reported examining the successful discontinuation of renal replacement therapies all studies reported to-date are observational in nature. Conventional biochemical criteria have been used as well as physiological parameters including urine output. More recently, more novel biomarkers of renal function have been studied. Although to-date no optimal variable nor threshold for discontinuation can be established. Several variables have been described which may have a role in determining which patients may be successfully weaned from renal replacement therapy. However, few have been exposed to vigorous examination and evidence is sparse in support of any potential approach although urine output currently is the most often described. More recently novel biomarkers have also been examined but again are limited by study design and heterogeneity. Further research is clearly needed focussing on proposed variables preferably in multivariate models to improve predictive ability and successful cessation of therapy.
Identifiants
pubmed: 37909367
doi: 10.1097/MCC.0000000000001101
pii: 00075198-202312000-00007
doi:
Substances chimiques
Biomarkers
0
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
559-565Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Références
Hoste EA, Bagshaw SM, Bellomo R, et al. Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study. Intensive Care Med 2015; 41:1411–1423.
Vincent JL, Sakr Y, Sprung CL, et al. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med 2006; 34:344–353.
Faubel S, Shah PB. Immediate consequences of acute kidney injury: the impact of traditional and nontraditional complications on mortality in acute kidney injury. Adv Chronic Kidney Dis 2016; 23:179–185.
Gallagher M, Cass A, Bellomo R, et al. Long-term survival and dialysis dependency following acute kidney injury in intensive care: extended follow-up of a randomized controlled trial. PLoS Med 2014; 11:e1001601.
Prowle JR, Bellomo R. Continuous renal replacement therapy: recent advances and future research. Nat Rev Nephrol 2010; 6:521–529.
Zarbock A, Kellum JA, Schmidt C, et al. Effect of early vs delayed initiation of renal replacement therapy on mortality in critically ill patients with acute kidney injury: the ELAIN randomized clinical trial. JAMA 2016; 315:2190–2199.
Bagshaw SM, Wald R, Adhikari NKJ, et al. Timing of initiation of renal-replacement therapy in acute kidney injury. N Engl J Med 2020; 383:240–251.
Katulka RJ, Al Saadon A, Sebastianski M, et al. Determining the optimal time for liberation from renal replacement therapy in critically ill patients: a systematic review and meta-analysis (DOnE RRT). Crit Care 2020; 24:50.
Ouellette DR, Patel S, Girard TD, et al. Liberation from mechanical ventilation in critically ill adults: an Official American College of Chest Physicians/American Thoracic Society Clinical Practice Guideline: Inspiratory Pressure Augmentation During Spontaneous Breathing Trials, protocols minimizing sedation, and noninvasive ventilation immediately after extubation. Chest 2017; 151:166–180.
Boles J-M, Bion J, Connors A, et al. Weaning from mechanical ventilation. Eur Respir J 2007; 29:1033–1056.
Uchino S, Bellomo R, Morimatsu H, et al. Discontinuation of continuous renal replacement therapy: a post hoc analysis of a prospective multicenter observational study. Crit Care Med 2009; 37:2576–2582.
Klouche K, Gibney RTN, Forni LG. Can this patient be safely weaned from RRT? Intensive Care Med 2018; 44:639–642.
Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract 2012; 120:c179–c184.
Jeon J, Kim DH, Baeg SI, et al. Association between diuretics and successful discontinuation of continuous renal replacement therapy in critically ill patients with acute kidney injury. Crit Care 2018; 22:255.
Yang T, Sun S, Lin L, et al. Predictive factors upon discontinuation of renal replacement therapy for long-term chronic dialysis and death in acute kidney injury patients. Artif Organs 2017; 41:1127–1134.
Gaudry S, Hajage D, Schortgen F, et al. Initiation strategies for renal-replacement therapy in the intensive care unit. N Engl J Med 2016; 375:122–133.
Marshall MR, Creamer JM, Foster M, et al. Mortality rate comparison after switching from continuous to prolonged intermittent renal replacement for acute kidney injury in three intensive care units from different countries. Nephrol Dial Transplant 2011; 26:2169–2175.
Collie JTB, Greaves RF, Jones OAH, et al. Vitamin B1 in critically ill patients: needs and challenges. Clin Chem Lab Med 2017; 55:1652–1668.
Yoshida T, Matsuura R, Komaru Y, et al. Kinetic estimated glomerular filtration rate as a predictor of successful continuous renal replacement therapy discontinuation. Nephrology 2019; 24:287–293.
Uchino S, Bellomo R, Morimatsu H, et al. Discontinuation of continuous renal replacement therapy: a post hoc analysis of a prospective multicenter observational study∗. Crit Care Med 2009; 37:2576–2582.
Katayama S, Uchino S, Uji M, et al. Factors predicting successful discontinuation of continuous renal replacement therapy. Anaesth Intensive Care 2016; 44:453–457.
Raurich JM, Llompart-Pou JA, Novo MA, et al. Successful weaning from continuous renal replacement therapy. Associated risk factors. J Crit Care 2018; 45:144–148.
Chawla LS, Davison DL, Brasha-Mitchell E, et al. Development and standardization of a furosemide stress test to predict the severity of acute kidney injury. Crit Care 2013; 17:R207.
Powell TC, Warnock DG. The furosemide stress test and predicting AKI outcomes. J Am Soc Nephrol 2015; 26:1762.
van der Voort PH, Boerma EC, Koopmans M, et al. Furosemide does not improve renal recovery after hemofiltration for acute renal failure in critically ill patients: a double blind randomized controlled trial. Crit Care Med 2009; 37:533–538.
van der Voort PH, Boerma EC, Pickkers P. The furosemide stress test to predict renal function after continuous renal replacement therapy. Crit Care 2014; 18:429.
Viallet N, Brunot V, Kuster N, et al. Daily urinary creatinine predicts the weaning of renal replacement therapy in ICU acute kidney injury patients. Ann Intensive Care 2016; 6:71.
Fröhlich S, Donnelly A, Solymos O, Conlon N. Use of 2-h creatinine clearance to guide cessation of continuous renal replacement therapy. J Crit Care 2012; 27: 744.e1-e5.
Intensity of renal support in critically ill patients with acute kidney injury. N Engl J Med 2008; 359:7–20.
Aniort J, Ait Hssain A, Pereira B, et al. Daily urinary urea excretion to guide intermittent hemodialysis weaning in critically ill patients. Crit Care 2016; 20:43.
O'Sullivan ED, Doyle A. The clinical utility of kinetic glomerular filtration rate. Clin Kidney J 2016; 10:202–208.
Dewitte A, Joannès-Boyau O, Sidobre C, et al. Kinetic eGFR and novel AKI biomarkers to predict renal recovery. Clin J Am Soc Nephrol 2015; 10:1900–1910.
Schetz M, Gunst J, Van den Berghe G. The impact of using estimated GFR versus creatinine clearance on the evaluation of recovery from acute kidney injury in the ICU. Intensive Care Med 2014; 40:1709–1717.
Schetz M, Gunst J, De Vlieger G, Van den Berghe G. Recovery from AKI in the critically ill: potential confounders in the evaluation. Intensive Care Med 2015; 41:1648–1657.
Forni LG, Darmon M, Ostermann M, et al. Renal recovery after acute kidney injury. Intensive Care Med 2017; 43:855–866.
Srisawat N, Wen X, Lee M, et al. Urinary biomarkers and renal recovery in critically ill patients with renal support. Clin J Am Soc Nephrol 2011; 6:1815–1823.
Chen X, Chen Z, Wei T, et al. The effect of serum neutrophil gelatinase-associated lipocalin on the discontinuation of continuous renal replacement therapy in critically ill patients with acute kidney injury. Blood Purif 2019; 48:10–17.
Han SS, Bae E, Song SH, et al. NT-proBNP is predictive of the weaning from continuous renal replacement therapy. Tohoku J Exp Med 2016; 239:1–8.
Komaru Y, Oguchi M, Sadahiro T, et al. Urinary neutrophil gelatinase-associated lipocalin and plasma IL-6 in discontinuation of continuous venovenous hemodiafiltration for severe acute kidney injury: a multicenter prospective observational study. Ann Intensive Care 2023; 13:42.
Delanaye P, Cavalier E, Morel J, et al. Detection of decreased glomerular filtration rate in intensive care units: serum cystatin C versus serum creatinine. BMC Nephrol 2014; 15:9.
Kim Chang S, Bae Eun H, Ma Seong K, Kim Soo W. A prospective observational study on the predictive value of serum cystatin C for successful weaning from continuous renal replacement therapy. Kidney Blood Press Res 2018; 43:872–881.
Zhang Z, Xu X, Ni H, Jin N. Serum cystatin C is associated with renal function recovery in critically ill patients undergoing continuous renal replacement therapy. Nephron Clin Pract 2012; 122:86–92.
Baas MC, Bouman CS, Hoek FJ, et al. Cystatin C in critically ill patients treated with continuous venovenous hemofiltration. Hemodial Int 2006; 10: (Suppl 2): S33–S37.
Kiers HD, de Sevaux R, Pickkers P. Cystatin C is not a reliable marker of residual glomerular filtration rate during continuous renal replacement therapy. Intensive Care Med 2011; 37:1893–1894. author reply 7–8.
Hollinger A, Wittebole X, François B, et al. Proenkephalin A 119-159 (Penkid) is an early biomarker of septic acute kidney injury: the Kidney in Sepsis and Septic Shock (Kid-SSS) study. Kidney Int Rep 2018; 3:1424–1433.
Beunders R, van Groenendael R, Leijte GP, et al. Proenkephalin compared to conventional methods to assess kidney function in critically ill sepsis patients. Shock 2020; 54:308–314.
von Groote T, Albert F, Meersch M, et al. Proenkephalin A 119-159 predicts early and successful liberation from renal replacement therapy in critically ill patients with acute kidney injury: a post hoc analysis of the ELAIN trial. Crit Care 2022; 26:333.
Baeg SI, Jeon J, Yoo H, et al. A scoring model with simple clinical parameters to predict successful discontinuation of continuous renal replacement therapy. Blood Purif 2021; 50:779–789.
Liu C, Peng Z, Dong Y, et al. Predicting successful continuous renal replacement therapy liberation in critically ill patients with acute kidney injury. J Crit Care 2021; 66:6–13.
Wald R, Beaubien-Souligny W, Chanchlani R, et al. Delivering optimal renal replacement therapy to critically ill patients with acute kidney injury. Intensive Care Med 2022; 48:1368–1381.
Schiffl H. Discontinuation of renal replacement therapy in critically ill patients with severe acute kidney injury: predictive factors of renal function recovery. Int Urol Nephrol 2018; 50:1845–1851.